Allogeneic haematopoietic stem cell transplantation is used to treat a variety of disorders,
but its efficacy is limited by the occurrence of graft-versus-host disease (GVHD). The past …

Allogeneic blood or bone-marrow transplantation (alloBMT) is a potentially curative
treatment for a variety of haematological malignancies and nonmalignant diseases …

PURPOSE Severe (grade 3-4) acute graft-versus-host disease (AGVHD) is a major cause of
death after unrelated-donor (URD) hematopoietic cell transplant (HCT), resulting in …

Potent immunosuppressive drugs have significantly improved early patient survival after
liver transplantation (LT). However, long‐term results remain unsatisfactory because of …

Haemopoietic-cell transplantation (HCT) is an intensive therapy used to treat high-risk
haematological malignant disorders and other life-threatening haematological and genetic …

We evaluated the safety and efficacy of high-dose, posttransplantation cyclophosphamide
(Cy) to prevent graft rejection and graft-versus-host disease (GVHD) after outpatient …

Allogeneic hematopoietic stem cell transplantation (alloSCT) is a potentially curative therapy
for many hematologic and immunologic diseases. Further, partial or full donor hematopoietic …

Recent advances in the understanding of T cell activation have led to new therapeutic
approaches in the treatment of immunological disorders. One attractive target of intervention …

Cyclophosphamide (Cy) is a potent immunosuppressive agent that is selectively toxic to
lymphocytes proliferating in response to recent antigen stimulation. In animal models, both …

Optimal immune responses require both an antigen-specific and a co-stimulatory signal. The
shared ligands B7-1 and B7-2 on antigen-presenting cells deliver the co-stimulatory signal …